| Document |
Document Title |
|
WO/2022/217859A1 |
Disclosed in the present invention are a bisindole alkaloid compound, and a synthesis method therefor and the use thereof. The compound has a structure as shown in formula I, wherein R1 is independently selected from C1-C4 alkoxy or hydr...
|
|
WO/2022/216762A1 |
Provided herein are acyclic oxazepinyl compounds useful in the treatment on cancers.
|
|
WO/2022/214102A1 |
Provided in the present invention is a compound acting as a KRAS G12D inhibitor; specifically provided in the present invention is a compound of the structure shown in the following formula (I), or an optical isomer, a pharmaceutically a...
|
|
WO/2022/216961A1 |
In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to compounds and methods for activating NAMPT in a subject. The compounds described herein are ...
|
|
WO/2022/217042A1 |
The invention provides naphthyl-substituted quinolin-4(1H)-ones and related compounds, pharmaceutical compositions, their use for inhibiting K-Ras G12D activity, and their use in the treatment of medical disorders, such as cancer.
|
|
WO/2022/213854A1 |
The present invention relates to a series of carbazole derivative and a use thereof. The structural formula of the carbazole derivative is as shown in formula (I). The present carbazole derivative has high stability and triplet energy le...
|
|
WO/2022/213896A1 |
The present invention provides a quinoxaline compound, a preparation method, and a pharmaceutical application thereof, and particularly relates to a quinoxaline compound having PAR4 antagonistic activity and a preparation method therefor...
|
|
WO/2022/207752A1 |
A compound comprising the formula (I), wherein each X1 is independently selected from C, N, O and S; each Y is independently selected from C and N; Z1 is independently selected from C and N; each X1 may independently be unsubstituted, or...
|
|
WO/2022/206724A1 |
The present invention relates to a heterocyclic derivative, and a preparation method therefor and an application thereof in medicine. In particular, the present invention relates to a heterocyclic derivative represented by general formul...
|
|
WO/2022/205592A1 |
Disclosed are a benzothiophene benzo five-membered heterocycle material, a preparation method therefor, and an application thereof. The material has a formula represented by structural general formula (I), wherein aromatic rings Ar1 and ...
|
|
WO/2022/212818A1 |
Described are 6-aryl [1,2,4]triazolo[4,3-a]pyridin-3(2H)-ones as negative allosteric modulators of metabotropic glutamate receptor 2 (mGlu2), pharmaceutical compositions including the compounds, and methods of using the compounds and com...
|
|
WO/2022/206723A1 |
The present invention relates to a heterocyclic derivative, and a preparation method therefor and the use thereof in medicine. Specifically, the present invention relates to a heterocyclic derivative as represented by general formula (A-...
|
|
WO/2022/204184A1 |
The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.
|
|
WO/2022/199656A1 |
Disclosed are a pharmaceutical combination, a kit containing same, and the use thereof in the preparation of a drug for treating breast cancer. The pharmaceutical combination comprises a first active ingredient and a second active ingred...
|
|
WO/2022/204452A1 |
The present application relates to compounds of formula (I'), pharmaceutically acceptable compositions thereof, and methods of using the same. The compounds of formula I' are TEAD inhibitors, useful in the treatment of cancer.
|
|
WO/2022/199586A1 |
The present invention relates to a pyrimidopyridine inhibitor, a preparation method therefor, and a use thereof. Specifically, the compound of the present invention has a structure represented by formula (I). Further disclosed in the pre...
|
|
WO/2022/200580A1 |
The present invention relates to compounds of general formula (I) inhibiting Discoidin Domain Receptors (DDR inhibitors), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof.The co...
|
|
WO/2022/198905A1 |
The present invention relates to a tricyclic derivative, and a preparation method therefor and an application thereof in medicines. Specifically, the present invention relates to a tricyclic derivative represented by general formula (I),...
|
|
WO/2022/204112A1 |
Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or d...
|
|
WO/2022/199464A1 |
The present invention relates to a series of carbazole derivatives and an application thereof, and an organic electroluminescent element, a display device and a lighting device containing the carbazole derivatives. The structural formula...
|
|
WO/2022/196634A1 |
An organic electroluminescent element (1) which comprises a positive electrode (3), a negative electrode (4), and a light emitting layer (5) that is interposed between the positive electrode (3) and the negative electrode (4), wherein: t...
|
|
WO/2022/193871A1 |
The present invention relates to a KRASG12D inhibitor and the use thereof, and in particular, provided is a compound as shown in a formula (I), wherein each substituent in the formula is defined in the description. Furthermore, the prese...
|
|
WO/2022/194779A1 |
The present invention relates to a compounds of general formula (I) inhibiting the JAK family of non-receptor tyrosine protein kinases (JAK1, JAK2, JAK3, and TYK2), methods of preparing such compounds, pharmaceutical compositions contain...
|
|
WO/2022/197756A1 |
The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
|
|
WO/2022/194267A1 |
A GPR84 antagonist, and a preparation method therefor and a use thereof, specifically a compound represented by formula (I), and a tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt, or prodrug thereof. The compou...
|
|
WO/2022/194192A1 |
The present invention relates to a compound represented by formula I or a pharmaceutically acceptable salt, a stereoisomer, a tautomer, a polymorph, a solvate, an N-oxide, an isotope labeled compound or a metabolite thereof, a pharmaceut...
|
|
WO/2022/197913A1 |
This disclosure provides chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit epidermal growth factor receptor (EGFR, ERBB1) an...
|
|
WO/2022/194781A1 |
The present invention relates to a compounds of general formula (I) inhibiting the JAK family of non-receptor tyrosine protein kinases (JAK1, JAK2, JAK3, and TYK2); methods of preparing such compounds, pharmaceutical compositions contain...
|
|
WO/2022/194066A1 |
Provided are a compound having KRAS G12D modulating activity, a preparation method for same, and a pharmaceutical composition comprising same.
|
|
WO/2022/194906A1 |
The present invention relates to the compounds (I) wherein the integers are as defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of tuberculosis.
|
|
WO/2022/196528A1 |
A compound which is represented by formula (I) or a salt thereof. In addition, a herbicide which contains, as an active ingredient, at least one substance that is selected from among the above-described compound and salt. In the formula ...
|
|
WO/2022/194909A2 |
The present invention relates to a process for the preparation of 7-(4,7- diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyri
dazin-6-yl)pyrido[1,2- a]pyrimidin-4-one derivatives useful as pharmaceutically active compounds.
|
|
WO/2022/187965A1 |
The present disclosure provides compounds and methods for inhibiting DNA-dependent protein kinase (DNA-PK). Aspects of the present disclosure also include methods of using the compounds to treat diseases, including, but not limited to, c...
|
|
WO/2022/188792A1 |
The present invention relates to a compound of formula (I), a pharmaceutical composition comprising same, a preparation method therefor, and a use thereof for preventing or treating tumor-related diseases or conditions.
|
|
WO/2022/192145A1 |
One embodiment of the disclosureis a compound represented by Formula I or a pharmaceutically acceptable salt thereof. The variables in Formula I are defined herein. Compounds of Formula I are MAP4K1 inhibitors, which can be used to treat...
|
|
WO/2022/188802A1 |
Provided is a use of Wee1 kinase inhibitors in the treatment of cancer. In particular, provided is a use of Wee1 kinase inhibitors in the preparation of drugs for the treatment of cancers with Histone H3K27M mutation.
|
|
WO/2022/188823A1 |
The present invention relates to the technical field of medicines, and in particular to a tricyclic HPK1 inhibitor compound or a pharmaceutically acceptable salt or stereoisomer thereof, a pharmaceutical composition and a preparation con...
|
|
WO/2022/190626A1 |
The problem to be solved by the present invention is to provide novel organic nano-particles and a novel compound for constituting the organic nano-particles. The present invention provides a compound represented by general formula (1) o...
|
|
WO/2022/187964A1 |
The present disclosure provides compounds and methods for inhibiting DNA-dependent protein kinase (DNA-PK). Aspects of the present disclosure also include methods of using the compounds to treat diseases, including, but not limited to, c...
|
|
WO/2022/187856A1 |
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
|
|
WO/2022/187588A1 |
The present disclosure relates to compounds of Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein A, X, J, Y, Z, n, and B1 are as defined as set forth in the specification. The present disclosure also rela...
|
|
WO/2022/184178A1 |
Provided are KRAS G12D inhibitors of formula (I) or formula (IV), a composition containing the inhibitor and the use thereof.
|
|
WO/2022/187520A1 |
The invention provides substituted 3-piperidinyl-pyrazolo[3,4-b]pyridines and related compounds, pharmaceutical compositions, their use for inhibiting ERK5 activity, and their use in the treatment of medical disorders, such as cancer.
|
|
WO/2022/187518A1 |
The invention provides substituted 4-pipcridinyl-imidazo[4,5-b]pyridincs and related compounds, pharmaceutical compositions, their use for inhibiting ERK5 activity, and their use in the treatment of medical disorders, such as cancer.
|
|
WO/2022/182415A1 |
The present disclosure provides compounds of Formula I, methods of preparing the compounds, compositions, kits, and methods of using the compounds for treating or preventing microbial infections.
|
|
WO/2022/180397A1 |
Pharmaceutical Compounds Benzodiazepine derivatives of formula (I): wherein: R1 is H or F; R2 is selected from formula (II) and formula (III) R3 is C1-C6 alkyl which is unsubstituted or substituted by CF3, or is a monocyclic 4- to 6-memb...
|
|
WO/2022/182839A1 |
The present application provides spirocyclic lactam compounds of Formula I that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
|
|
WO/2022/178256A1 |
The present disclosure relates compounds of Formula (I'): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparing the compounds, compositions comprising the compounds, ...
|
|
WO/2022/175675A1 |
The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in medicine; and methods of treating patients with such compounds; wherein A, W, V, Z, U, X, Y and B are as define...
|
|
WO/2022/178205A1 |
The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of protein kinases, and methods for their use in treating disorders mediated, at least in part by, protein kinases.
|
